Ernexa Therapeutics Inc.
ERNA
$4.27
-$0.03-0.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.88% | 14.78% | -7.92% | -71.67% | -64.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.09% | 29.89% | -22.39% | -53.89% | -49.76% |
| Operating Income | -64.09% | -29.89% | 22.36% | 48.03% | 49.28% |
| Income Before Tax | -27.84% | 32.32% | 72.79% | 95.36% | 43.25% |
| Income Tax Expenses | -- | -600.00% | -663.64% | -50.00% | 0.00% |
| Earnings from Continuing Operations | -27.72% | 32.87% | 73.92% | 95.34% | 43.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.72% | 32.87% | 73.92% | 95.34% | 43.23% |
| EBIT | -64.09% | -29.89% | 22.36% | 48.03% | 49.28% |
| EBITDA | -64.86% | -30.46% | 22.29% | 47.97% | 49.17% |
| EPS Basic | 77.66% | 87.96% | 91.89% | 99.80% | 96.04% |
| Normalized Basic EPS | 77.40% | 92.34% | 92.70% | 98.49% | 96.09% |
| EPS Diluted | 77.66% | 87.96% | 91.89% | 99.80% | 96.04% |
| Normalized Diluted EPS | 77.40% | 92.34% | 92.70% | 98.49% | 96.09% |
| Average Basic Shares Outstanding | 471.50% | 457.75% | 222.87% | 2,184.72% | 1,337.50% |
| Average Diluted Shares Outstanding | 471.50% | 457.75% | 222.87% | 2,184.72% | 1,337.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |